Skip to main content
SpringerLink
Log in

Cetuximab

A Review of its Use in Squamous Cell Carcinoma of the Head and Neck

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in most squamous cell carcinomas of the head and neck (SCCHN); this overexpression is associated with more aggressive disease and poorer prognosis. In the EU, cetuximab is approved in combination with radiation therapy for the treatment of locally advanced SCCHN and in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic SCCHN.

In randomized, open-label, multinational, phase III clinical trials, cetuximab plus radiotherapy significantly improved the duration of locoregional control (primary endpoint) compared with radiotherapy alone in patients with locally advanced SCCHN, while cetuximab plus first-line platinum-based chemotherapy significantly improved overall survival (primary endpoint) compared with first-line platinum-based chemotherapy alone in patients with recurrent and/or metastatic SCCHN. The efficacy benefits of cetuximab-based combination therapy were achieved without an adverse impact on patients' health-related quality of life. In addition, cetuximab had an acceptable tolerability profile when added to radiotherapy or platinum-based chemotherapy; in particular, it did not exacerbate the toxicities commonly associated with these other treatment modalities. Cetuximab-related adverse events, which include skin rash, hypomagnesaemia and infusion-related reactions, are mostly mild to moderate in severity and manageable.

Thus, cetuximab-based combination therapy is a valuable treatment option in patients with SCCHN. In the setting of locally advanced, unresectable disease, cetuximab plus radiotherapy offers an alternative approach to the current standard of care, namely platinum-based chemotherapy plus radiotherapy (chemoradio-therapy). Based on informal comparisons, cetuximab plus radiotherapy appears to be at least as effective as chemoradiotherapy and, moreover, less toxic; however, formal comparisons of these regimens are required before their relative efficacy and tolerability can be conclusively determined. In the setting of recurrent and/or metastatic SCCHN, cetuximab plus platinum-based chemotherapy provides a first-line treatment of choice for fit patients in whom palliative chemotherapy is indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gleeson M. Head and neck cancer: the surgeon's role. Cancer Imaging 2001; 2: 40–50

    Google Scholar 

  2. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008 May 17; 371: 1695–709

    Article  PubMed  CAS  Google Scholar 

  3. Gregoire V, Lefebvre J-L, Licitra L, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl. 5: 184–6

    Article  Google Scholar 

  4. Curado MP, Hashibe M. Recent changes in the epidemiology of head and neck cancer. Curr Opin Oncol 2009 May; 21(3): 194–200

    Article  PubMed  Google Scholar 

  5. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008 Sep 11; 359(11): 1143–54

    Article  PubMed  CAS  Google Scholar 

  6. Ko C, Citrin D. Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. Oral Dis 2009 Mar 1; 15(2): 121–32

    Article  PubMed  CAS  Google Scholar 

  7. Ang KK. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. Oncologist 2008; 13: 899–910

    Article  PubMed  CAS  Google Scholar 

  8. Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67(17): 2585–607

    Article  PubMed  CAS  Google Scholar 

  9. Erbitux 5 mg/ml solution for infusion: summary of product characteristics. Darmstadt: Merck KGaA, 2010

  10. Rivera F, Vega-Villegas ME, López-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008; 19:99–113

    Article  PubMed  CAS  Google Scholar 

  11. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today 2005 Feb; 41(2): 107–27

    Article  PubMed  CAS  Google Scholar 

  12. European Medicines Agency. Erbitux European public assessment report: scientific discussion [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000558/WC500029113.pdf [Accessed 2010 Jun 10]

  13. Center for Drug Evaluation and Research. BLA-STN 1250840 Erbitux (cetuximab): clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov [Accessed 2010 Jun 10]

  14. Wujcik D. EGFR as a target: rationale for therapy. Semin Oncol Nurs 2006 Feb; 22 (1 Suppl. 1): 5–9

    Article  PubMed  Google Scholar 

  15. Adams G, Weiner L. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147–57

    Article  PubMed  CAS  Google Scholar 

  16. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 2006 Apr; 20 (5 Suppl. 2): 5–13

    PubMed  Google Scholar 

  17. Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 2009 Feb 15; 315(4): 572–82

    Article  PubMed  CAS  Google Scholar 

  18. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350–6

    PubMed  CAS  Google Scholar 

  19. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9–15

    Article  PubMed  CAS  Google Scholar 

  20. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005 Apr; 7(4): 301–11

    Article  PubMed  CAS  Google Scholar 

  21. Sunada H, Magun BE, Mendelsohn J, et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Nat Acad Sci U S A 1986 Jun; 83: 3825–9

    Article  CAS  Google Scholar 

  22. Huang S-M, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59(8): 1935–40

    PubMed  CAS  Google Scholar 

  23. Huang S-M, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002 May; 1: 507–14

    PubMed  CAS  Google Scholar 

  24. Wagenblast J, Baghi M, Môrtel S, et al. Does dexametha-sone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck? Oncol Rep 2009 Jul; 22(1): 171–6

    Article  PubMed  CAS  Google Scholar 

  25. Brown D, Wang R, Russell P. Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemother-apeutic agents on squamous cell carcinoma lines. Otolaryngol Head Neck Surg 2000 Jan; 122(1): 75–83

    Article  PubMed  CAS  Google Scholar 

  26. Huang S-M, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Can Res 2000 Jun; 6: 2166–74

    CAS  Google Scholar 

  27. Feng FY, Lopez CA, Normolle DP, et al. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 2007 Apr 15; 13(8): 2512–8

    Article  PubMed  CAS  Google Scholar 

  28. Zhang N, Erjala K, Kulmala J, et al. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 2009 Sep; 92(3): 388–92

    Article  PubMed  CAS  Google Scholar 

  29. Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007; 133(12): 1277–83

    Article  PubMed  Google Scholar 

  30. Taylor RJ, Chan SL, Wood A, et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009 Jul; 58(7): 997–1006

    Article  PubMed  CAS  Google Scholar 

  31. Lopez-Albaitero A, Lee SC, Morgan S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009 Nov; 58(11): 1853–64

    Article  PubMed  CAS  Google Scholar 

  32. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007; 39(1–3): 271–8

    Article  PubMed  CAS  Google Scholar 

  33. Stroh C, Reusch C, Schmidt J, et al. Pharmacological and immunological characteristics of the therapeutic anti-EGFR antibodies cetuximab, panitumumab, and nimotuzumab. J Clin Oncol 2010 May 20; 28 (15s; abstract no. e13025) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  34. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009 May; 21(3): 211–5

    Article  PubMed  Google Scholar 

  35. Bristol Myers Squibb. Erbitux® (cetuximab) solution for intravenous infusion: US prescribing information [online]. Available from URL: http://packageinserts.bms.com/pi/pi_erbitux.pdf [Accessed 2010 Apr 21]

  36. Delbaldo C, Pierga JY, Dieras V, et al. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer 2005 Aug; 41(12): 1739–45

    Article  PubMed  CAS  Google Scholar 

  37. Dirks NL, Nolting A, Kovar A, et al. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 2008 Mar; 48(3): 267–78

    Article  PubMed  CAS  Google Scholar 

  38. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007 Jun 1; 25(16): 2171–7

    Article  PubMed  CAS  Google Scholar 

  39. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006 Jun 20; 24(18): 2866–72

    Article  PubMed  CAS  Google Scholar 

  40. Roepstorff K, Grovdal L, Grandal M, et al. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol 2008; 129: 563–78

    Article  PubMed  CAS  Google Scholar 

  41. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 Feb 9; 354(6): 567–78

    Article  PubMed  CAS  Google Scholar 

  42. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010 Jan; 11(1): 21–8

    Article  PubMed  CAS  Google Scholar 

  43. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007 Jun 1; 25(16): 2191–7

    Article  PubMed  CAS  Google Scholar 

  44. European Medicines Agency. Erbitux-H-558-II-05 scientific discussion [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Apr 9]

  45. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005 Dec 1; 23(34): 8646–54

    Article  PubMed  Google Scholar 

  46. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008 Sep 11; 359(11): 1116–27

    Article  PubMed  CAS  Google Scholar 

  47. Mesia R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. Epub 2010 Mar 24

  48. Vermorken JB, Mesia R, Remenar E, et al. Predictors of efficacy in the EXTREME study: cetuximab plus platinum-based therapy first-line in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [abstract no. 687O]. Ann Oncol 2008 Sep; 19 Suppl. 8: 217

    Google Scholar 

  49. Mesia R, Remenar E, Benasso M, et al. Cetuximab plus platinum-based chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: analyzing the predictive value of biomarkers in the extreme study [abstract no. IC/AB529]. 20th International Congress on Anti-Cancer Treatment; 2009 Feb 3–6; Paris

  50. Licitra L, Rolland F, Bokemeyer C, et al. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: platinum-based CT plus cetuximab in first-line R/M SCCHN. J Clin Oncol 2009 May 20; 27: 15s

    Article  Google Scholar 

  51. Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008 Sep; 11(5): 791–9

    Article  PubMed  Google Scholar 

  52. De Abreu Lourenco R, Houltram J, Pearce G. Assessment of the cost-effectiveness in Australia of cetuximab in the treatment of patients with locally advanced squamous cell cancers of the head and neck. Value Health 2007 Nov; 10(6): 326

    Article  Google Scholar 

  53. Brosa M, Robinson P, Brown B. Cost-effectiveness of cetuximab in combination with radiotherapy versus radiotherapy alone in the treatment of locally advanced head and neck cancer in Spain. Value Health 2006 Nov; 9(6): A281

    Article  Google Scholar 

  54. Sambrook J, Levy AR, Johnston KM, et al. Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck in Canada. J Clin Oncol 2009 May 20; 27 (15s; abstract no. e17000) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  55. Griffin S, Walker S, Sculpher M, et al. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Health Technol Assess 2009 Jun; 13 Suppl. 1: 49–54

    PubMed  Google Scholar 

  56. Greenhalgh J, Bagust A, Boland A, et al. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technol Assess 2009 Oct; 13 Suppl. 3: 49–54

    PubMed  Google Scholar 

  57. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics 2010 Jun; 28(6): 439–48

    Article  PubMed  Google Scholar 

  58. Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nurs 2005 Jun; 9(3): 332–8

    Article  PubMed  Google Scholar 

  59. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002 Oct; 29 (5 Suppl. 14): 55–60

    PubMed  CAS  Google Scholar 

  60. Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology 2006 Oct; 20(11): 1373–82

    PubMed  Google Scholar 

  61. Liu L, Cao Y, Tan A, et al. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol 2010 Apr; 65(5): 849–61

    Article  PubMed  CAS  Google Scholar 

  62. Cao Y, Liu L, Liao C, et al. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol 2010 May; 66(1): 37–42

    Article  PubMed  CAS  Google Scholar 

  63. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007 Nov 15; 357(20): 2040–8

    Article  PubMed  CAS  Google Scholar 

  64. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007 Mar; 6(2): 175–82

    Article  PubMed  CAS  Google Scholar 

  65. Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005 Aug 17; 97(16): 1221–4

    Article  PubMed  CAS  Google Scholar 

  66. Chaudhary P, Gajra A. Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies. Cardiovasc Hematol Agents Med Chem 2010 Jul; 8(3): 156–63

    Article  PubMed  CAS  Google Scholar 

  67. Hoag JB, Azizi A, Doherty TJ, et al. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 2009 Aug 14; 28: 113

    Article  PubMed  Google Scholar 

  68. Center for Drug Evaluation and Research. BLA-STN 1250840 Erbitux (cetuximab): medical review part 2 [online]. Available from URL: http://www.accessdata.fda.gov [Accessed 2010 Aug 30]

  69. Saif MW, Syrigos KL, Hotchkiss S, et al. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2009 Dec; 65(1): 107–12

    Article  PubMed  CAS  Google Scholar 

  70. Siena S, Glynne-Jones R, Adenis A, et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 2010 Apr 1; 116: 1827–37

    Article  PubMed  CAS  Google Scholar 

  71. Cerman J, Melichar B, Cermanova M, et al. Management of severe infusion reactions after cetuximab. Acta Oncol 2008; 47(8): 1609–11

    Article  PubMed  Google Scholar 

  72. Bonner J, Harari P, Giralt J, et al. Duration of mucositis and dysphagia following radiotherapy (+/-cetuximab) for locoregionally advanced head and neck cancer [plenary 4]. The Multidisciplinary Head and Neck Cancer Symposium; 2007 Jan 18–20; Rancho Mirage (CA)

  73. Merck KGaA. Erbitux 2 mg/ml solution for infusion: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-en.pdf [Accessed 2010 Apr 21]

  74. Scarpace SL, Brodzik FA, Mehdi S, et al. Treatment of head and neck cancers: issues for clinical pharmacists. Pharmacotherapy 2009 May; 29(5): 578–92

    Article  PubMed  Google Scholar 

  75. Cohen EEW, Lingen MW, Vokes VE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004 May 1; 22(9): 1743–52

    Article  PubMed  Google Scholar 

  76. Pignon JP, le Maýtre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiother Oncol 2009 Jul; 92(1): 4–14

    Article  PubMed  Google Scholar 

  77. Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med 2006 Feb 9; 354(6): 634–5

    Article  PubMed  CAS  Google Scholar 

  78. Burri RJ, Lee NY. Concurrent chemotherapy and radiotherapy for head and neck cancer. Expert Rev Anticancer Ther 2009 Mar; 9(3): 293–302

    Article  PubMed  Google Scholar 

  79. Lorch JH, Posner MR, Wirth LJ, et al. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am 2008 Dec; 22(6): 1155–63

    Article  PubMed  Google Scholar 

  80. Bernier J. Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck [online]. Oncol Rev 2009 Oct 20

  81. NCCN Clinical Practice Guidelines in Oncology. Head and neck cancers. Version 1 2010 [online]. Available from URL: http://www.nccn.org [Accessed 2010 Jun 24]

  82. Harrington KJ. Rash conclusions from a phase 3 study of cetuximab? Lancet Oncol 2010 Jan; 11(1): 2–3

    Article  PubMed  Google Scholar 

  83. Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer 2007 Jan; 43(1): 35–45

    Article  PubMed  CAS  Google Scholar 

  84. Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008 Jul 1; 71(3): 676–81

    Article  PubMed  CAS  Google Scholar 

  85. Koutcher L, Fury M, Wolden S, et al. Comparison of cisplatin and radiation (RT) to cetuximab and RT for locally advanced head and neck cancer: a preliminary analysis. J Clin Oncol 2009 May 20; 27 (15s; abstract no. 6042) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  86. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010 Jan; 28(1): 8–14

    Article  PubMed  CAS  Google Scholar 

  87. Haddad RI, Tishler RB, Norris C, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009 Sep 20; 27(27): 4448–53

    Article  PubMed  CAS  Google Scholar 

  88. Mesia R, Vazquez S, Grau JJ, et al. A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil as induction chemotherapy in patients with unresectable SCCHN. J Clin Oncol 2009 May 20; 27 (15s; abstract no. 6015) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  89. Kuperman DI, Nussenbaum B, Thorstad W, et al. Retrospective analysis of the addition of cetuximab to induction chemotherapy with docetaxel, cisplatin, and 5-flurouracil for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2007 Jun 20; 25 (18s; abstract no. 6072) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  90. Kuperman DI, Ley J, Nussenbaum B, et al. Clinical response rate at primary tumor site by WHO criteria following an induction chemotherapy regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2010May 20; 28 (15s; abstract no. e16028) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  91. Billan S, Abdah-Bortnyak R, Mezid F, et al. Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil before concurrent chemoradiotherapy or concurrent cetuximab-radiotherapy in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009 May 20; 27 (15s; abstract no. e17045) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  92. Buiret G, Combe C, Favrel V, et al. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010 Jun 1; 77(2): 430–7

    Article  PubMed  CAS  Google Scholar 

  93. Calvo M, Vazquez S, Lozano A, et al. Induction chemotherapy followed by concomitant radiotherapy plus cetuximab in patients with unresectable advanced head and neck cancer [abstract no. 700P]. Ann Oncol 2008 Sep; 19 Suppl. 8: 221

    Google Scholar 

  94. Mercke C, Wickart-Johansson G, Sjodin H, et al. Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer. J Clin Oncol 2009 May 20; 27 (15s; abstract no. 6040) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  95. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006 Mar 1; 24(7): 1072–8

    Article  PubMed  CAS  Google Scholar 

  96. Langer CJ, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: Concurrent radiation, cisplatin, and cetuximab in unresectable, locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2008 May 20; 26 (15s; abstract 6006) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  97. Kuhnt T, Sandner A, Wendt T, et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol. Epub 2010 Apr 28

  98. Koukourakis MI, Tsoutsou PG, Karpouzis A. Radio-chemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2010 May 1; 77(1): 9–15

    Article  PubMed  CAS  Google Scholar 

  99. Merlano MC, Benasso M, Numico G, et al. Chemo-radiation (CTRT) and cetuximab (CMAB) in locally advanced head and neck cancer (LA HNC) [abstract no. 694PD]. Ann Oncol 2008 Sep; 19 Suppl. 8: 219

    Google Scholar 

  100. Kao J, Policarpio L, Teng M, et al. Phase II trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and intensity modulated radiation therapy for locally advanced head and neck cancer. J Clin Oncol 2009 May 20; 27 (15s; abstract no. 6014) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  101. Birnbaum A, Dipetrillo T, Rathore R, et al. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol 2010 Apr; 33(2): 144–7

    PubMed  CAS  Google Scholar 

  102. Wanebo HJ, Ghebremichael M, Burtness B, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin and radiation for stage III/IV operable squamous cancer of head and neck (ECOG, E2303). J Clin Oncol 2007 Jun 20; 25 (18s; abstract no. 6015) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  103. Argiris AE, Gibson MK, Heron DE, et al. Phase II trial of neoadjuvant docetaxel, cisplatin (P), and cetuximab (E) followed by concurrent radiation, P, and E in locally advanced head and neck cancer. J Clin Oncol 2008 May 20; 26 (15s; abstract 6002) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  104. Perri F, Longo F, Ionna F, et al. Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck. OncoTargets Ther 2009; 2: 243–50

    CAS  Google Scholar 

  105. Bourhis J, Lefebvre JL, Vermorken JB. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options. Eur J Cancer 2010 Jul; 46(11): 1979–89

    Article  PubMed  CAS  Google Scholar 

  106. Lefebvre J, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy for larynx preservation: preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol 2009 May 20; 27 (15s; abstract no. 6010) [online]. Available from URL: http://www.abstract.asco.org [Accessed 2010 Jul 1]

  107. Ang K, Axelrod R, Sherman E, et al. A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin and cetuximab (C225) [followed by surgery for selected patients] for stage III and IV head and neck carcinomas [online]. Available from URL: http://www.rtog.org/members/protocols/0522/0522.pdf [Accessed 2010 Sep 22]

  108. ClinicalTrials.gov. Randomized trial of concomitant chemotherapy in patients with locally advanced HNSCC treated by radiotherapy-erbitux (GORTEC2007-01) [Clinical Trials.gov identifier NCT00609284]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jun 29]

  109. Radiation Therapy Oncology Group. Committee minutes-head and neck cancer [online]. Available from URL: http://www.rtog.org/committees/minutes/headneck.html [Accessed 2010 Jun 29]

  110. Petrelli NJ, Winer EP, Brahmer J, et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening. A report from the American Society of Clinical Oncology. J Clin Oncol 2009 Dec 10; 27(35): 6052–69

    Article  PubMed  Google Scholar 

  111. Merlano MC, Vermorken JB, Wilke H, et al. First-line treatment patterns for recurrent and/or metastatic head and neck cancer (R/M HNC) in Europe. J Clin Oncol 2010 May 20; 28 (15s; abstract no. e16016) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  112. Hitt R, Irigoyen A, Nunez J, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck: Spanish Head and Neck Cancer Group. J Clin Oncol 2007 Jun 20; 25 (18s; abstract no. 6012) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  113. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005 Aug 20; 23(24): 5578–87

    Article  PubMed  CAS  Google Scholar 

  114. Balsega J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005 Aug 20; 23(24): 5568–77

    Article  Google Scholar 

  115. Knoedler MK, Gauler T, Matzdorff A, et al. Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. J Clin Oncol 2009 May 20; 27 (15s; abstract no. 6048) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  116. Buentzel J, de Vries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol 2007 Jun 20; 25 (18s; abstract no. 6077) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

  117. Tejani MA, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics 2010; 4: 173–85

    PubMed  CAS  Google Scholar 

  118. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008 Jan; 19(1): 142–9

    Article  PubMed  CAS  Google Scholar 

  119. Lang K, Menzin J, Earle CE, et al. The economic cost of squamous cell cancer of the head and neck. Arch Otolar-yngol Head Neck Surg 2004; 130: 1269–75

    Article  Google Scholar 

  120. Rivera F, Garcia-Castano A, Vega N, et al. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther 2009 Oct; 9(10): 1421–8

    Article  PubMed  CAS  Google Scholar 

  121. Giovannini M, Gregorc V, Belli C, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oncol. Epub 2009 Jun 22

  122. Weber A, Langhanki L, Sommerer F, et al. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 2003 Jul 24; 22(30): 4757–9

    Article  PubMed  CAS  Google Scholar 

  123. Wang LX, Agulnik M. Promising newer molecular-targeted therapies in head and neck cancer. Drugs 2008; 68(12): 1609–19

    Article  PubMed  CAS  Google Scholar 

  124. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010 Feb; 21(2): 342–7

    Article  PubMed  CAS  Google Scholar 

  125. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010 Jul 10; 28(20): 3330–5

    Article  PubMed  CAS  Google Scholar 

  126. Gibson MK, Kies M, Kim S, et al. Cetuximab and bevacizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an updated report. J Clin Oncol 2009 May 20; 27 (15s; abstract no. 6049) [online]. Available from URL: http://meeting.ascopubs.org [Accessed 2010 Jul 1]

Download references

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. Cetuximab. Drugs 70, 1987–2010 (2010). https://doi.org/10.2165/11205010-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205010-000000000-00000

Keywords

Search

Navigation